Industry Reports
Bristol-Myers Squibb to Announce Results for First Quarter 2013 on April 25
Bristol-Myers Squibb Company will announce results for the first quarter of 2013 on Thursday April 25 2013. During a conference call at 10:30 a.m. EDT on April 25 company executives will review financial information and will address inquiries...
Industry Reports
A strong cash position of EUR 30.5 million, an annual loss of EUR 6.0 million and significant clinical progress of Adocia projects
Adocia, a biotechnology company specialized in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announces today its financial results for 2012. The financial statements were approved by the board of directors of...
Industry Reports
Adocia reports 2012 revenue multiplied by 2.5 with a strong cash position
Adocia , a biotechnology company specialized in the development of ‘best-in-class’ medicines with already approved therapeutic proteins, announces today its revenue for the full year and last quarter of 2012. Breakdown of the operating...
Industry Reports
Sanofi delivers solid 2012 results despite patent expirations
In the fourth quarter of 2012, Sanofi generated sales of €8,526 million, an increase of 0.2% on a reported basis. Exchange rate movements had a positive effect of 1.9 percentage points primarily reflecting the appreciation of the U.S....
Industry Reports
Roche delivers strong 2012 results
Roche delivered a strong performance in 2012, with Group sales rising 4% to 45.5 billion Swiss francs due to growing demand for its cancer medicines and increased sales of diagnostic tests to clinical laboratories. This...
Industry Reports
AstraZeneca fourth quarter and full year results 2012
AstraZeneca's revenue in the fourth quarter was down 15 percent at constant exchange rates (CER) and declined by 16 percent on an actual basis as a result of the negative impact of exchange rate movements. Loss of exclusivity...
Industry Reports
Bristol-Myers Squibb reports fourth quarter financial results
Bristol-Myers Squibb Company has announced results for the fourth quarter of 2012 highlighted by regulatory approvals for Eliquis and Forxiga. This concluded a year in which the Company delivered growth of its key products...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
